BMI、降脂药物与年龄和杂合子家族性高胆固醇血症成人2型糖尿病患病率的关联:一项全球横断面研究
该全球横断面研究纳入44个国家24 784例杂合子家族性高胆固醇血症成人,2型糖尿病总患病率为5.7%(1415/24 784),基因确诊队列为4.1%(817/19 818)。年龄增长、BMI升高(超重和肥胖)及使用降脂药物与2型糖尿病风险升高相关,最高风险类别(55-98岁、肥胖、接受他汀)的OR为74.42(95%CI 47.04-117.73)。
要点
- 杂合子家族性高胆固醇血症成人2型糖尿病总患病率为5.7%(1415/24 784)。
- 肥胖显著增加年龄和他汀使用相关的糖尿病风险。
- 杂合子家族性高胆固醇血症似乎并不预防2型糖尿病,管理肥胖至关重要。
核心结论
- 大多数WHO区域的杂合子家族性高胆固醇血症成人2型糖尿病患病率高于欧洲。
- 肥胖显著增加这些患者中与年龄和他汀使用相关的糖尿病风险。
- 结果提示杂合子家族性高胆固醇血症并不预防2型糖尿病,因此管理肥胖对减少该人群2型糖尿病至关重要。
研究设计与样本
- 全球横断面研究,使用EAS FHSC登记处的个体水平数据。
- 纳入44个国家24 784例年龄大于18岁、临床或基因诊断的杂合子家族性高胆固醇血症成人,且有年龄、BMI和糖尿病状态数据。
- 排除已知或疑似纯合子家族性高胆固醇血症和1型糖尿病患者。
- 主要结局为总体及按WHO区域划分的2型糖尿病患病率,以及肥胖(BMI ≥30.0 kg/m2)和降脂药物作为预测因素。
- 研究人群按年龄(三分位数)、肥胖和接受他汀分为12个风险类别,使用逻辑回归分析2型糖尿病风险。
主要发现
- 总人群2型糖尿病患病率为5.7%(1415/24 784),基因确诊队列为4.1%(817/19 818)。
- 东地中海区域患病率为29.9%(58/194),东南亚和西太平洋区域为12.0%(214/1785),美洲为8.5%(166/1955),均高于欧洲(除荷兰外)的8.0%(527/6579)。
- 最高风险类别(55-98岁、肥胖、接受他汀)的2型糖尿病概率高于最低风险类别(18-38岁、无肥胖、未接受他汀),OR为74.42(95%CI 47.04-117.73)。
- 无肥胖者即使处于年龄上三分位且接受他汀,风险仍较低,OR为24.42(95%CI 15.57-38.31)。
- 基因确诊队列中,最高风险类别肥胖者的OR为65.04(95%CI 40.67-104.02),无肥胖者为20.07(95%CI 12.73-31.65)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Statins are the cornerstone treatment for patients with heterozygous familial hypercholesterolaemia but research suggests it could increase the risk of type 2 diabetes in the general population. A low prevalence of type 2 diabetes was reported in some familial hypercholesterolaemia cohorts, raising the question of whether these patients are protected against type 2 diabetes. Obesity is a well known risk factor for the development of type 2 diabetes. We aimed to investigate the associations of known key determinants of type 2 diabetes with its prevalence in people with heterozygous familial hypercholesterolaemia. METHODS: This worldwide cross-sectional study used individual-level data from the EAS FHSC registry and included adults older than 18 years with a clinical or genetic diagnosis of heterozygous familial hypercholesterolaemia who had data available on age, BMI, and diabetes status. Those with known or suspected homozygous familial hypercholesterolaemia and type 1 diabetes were excluded. The main outcome was prevalence of type 2 diabetes overall and by WHO region, and in relation to obesity (BMI ≥30·0 kg/m2) and lipid-lowering medication as predictors. The study population was divided into 12 risk categories based on age (tertiles), obesity, and receiving statins, and the risk of type 2 diabetes was investigated using logistic regression. FINDINGS: Among 46 683 adults with individual-level data in the FHSC registry, 24 784 with heterozygous familial hypercholesterolaemia were included in the analysis from 44 countries. 19 818 (80%) had a genetically confirmed diagnosis of heterozygous familial hypercholesterolaemia. Type 2 diabetes prevalence in the total population was 5·7% (1415 of 24 784), with 4·1% (817 of 19 818) in the genetically diagnosed cohort. Higher prevalence of type 2 diabetes was observed in the Eastern Mediterranean (58 [29·9%] of 194), South-East Asia and Western Pacific (214 [12·0%] of 1785), and the Americas (166 [8·5%] of 1955) than in Europe (excluding the Netherlands; 527 [8·0%] of 6579). Advancing age, a higher BMI category (obesity and overweight), and use of lipid-lowering medication were associated with a higher risk of type 2 diabetes, independent of sex and LDL cholesterol. Among the 12 risk categories, the probability of developing type 2 diabetes was higher in people in the highest risk category (aged 55-98 years, with obesity, and receiving statins; OR 74·42 [95% CI 47·04-117·73]) than in those in the lowest risk category (aged 18-38 years, without obesity, and not receiving statins). Those who did not have obesity, even if they were in the upper age tertile and receiving statins, had lower risk of type 2 diabetes (OR 24·42 [15·57-38·31]). The corresponding results in the genetically diagnosed cohort were OR 65·04 (40·67-104·02) for those with obesity in the highest risk category and OR 20·07 (12·73-31·65) for those without obesity. INTERPRETATION: Adults with heterozygous familial hypercholesterolaemia in most WHO regions have a higher type 2 diabetes prevalence than in Europe. Obesity markedly increases the risk of diabetes associated with age and use of statins in these patients. Our results suggest that heterozygous familial hypercholesterolaemia does not protect against type 2 diabetes, hence managing obesity is essential to reduce type 2 diabetes in this patient population. FUNDING: Pfizer, Amgen, MSD, Sanofi-Aventis, Daiichi-Sankyo, and Regeneron.
引用
- Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study. Lancet Diabetes Endocrinol. 2024. PMID: 39374602. doi:10.1016/S2213-8587(24)00221-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。